

[Revision log](#)

# CONCERT GENETICS GENETIC TESTING: EXOME AND GENOME SEQUENCING FOR THE DIAGNOSIS OF GENETIC DISORDERS

---

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## OVERVIEW

Exome sequencing (ES) (also known as ‘whole exome sequencing (WES)’) involves sequencing and copy number variant (CNV) analysis of the portion of the genome that contains protein-coding DNA, which are termed exons. Together, all of the exons in a genome are known as the exome, which constitutes approximately 1% of the genome and is currently estimated to contain about 85% of heritable disease-causing variants.

Genome sequencing (GS) (also known as ‘whole genome sequencing (WGS)’) is a comprehensive method that sequences both coding and noncoding regions of the genome. GS has typically been limited to use in the research setting, but is emerging in the clinical setting and has a greater ability to detect large deletions or duplications in protein-coding regions compared with ES. GS requires greater data analysis but less DNA preparation prior to sequencing.

ES and GS have been proposed for use in patients presenting with disorders and anomalies not immediately explained by standard clinical workup. Potential candidates for ES and GS include patients who present with a broad spectrum of suspected genetic conditions. GS has been shown to have a higher diagnostic yield compared to ES when used as a first line test. ES reanalysis is often performed approximately 18 months to 2 years following initial, uninformative ES. Studies have shown that the diagnostic yield of ES reanalysis is comparable to performing GS after an uninformative ES.

Rapid exome sequencing (rES) and rapid genome (rGS) sequencing involves sequencing of the exome or genome, respectively, in an accelerated time frame. Preliminary results can typically be returned in less than 7 days, and a final report in less than two weeks. Studies suggest that the use of rES or rGS in acutely-ill infants, presenting with complex phenotypes that are likely rare genetic conditions, can identify a genetic diagnosis more quickly, allowing clinicians and family members to change acute medical or surgical management options and end the diagnostic odyssey. Ultra-rapid GS involves sequencing of the genome typically in less than 72 hours and is currently considered investigational.

## POLICY REFERENCE TABLE

### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2022, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

Please see the [Concert Genetics Platform](#) for a comprehensive list of registered tests.

<a href="#">Criteria Sections</a>	Example Tests (Labs)	Common CPT Codes	Common ICD Codes	<a href="#">Ref</a>
<a href="#">Standard Exome Sequencing</a>	Genomic Unity Exome Plus Analysis - Proband (Variantyx)	0214U	F70-F79, F80.0-F89, Q00.0-Q99.9	1, 3, 5, 7, 9, 14
	Genomic Unity Exome Plus Analysis - Comparator (Duo or Trio) (Variantyx Inc.)	0215U		
	XomeDx - Proband (GeneDx)	81415		
	Exome - Proband Only (Invitae)			
	XomeDx - Duo (GeneDx)	81415, 81416		
	XomeDX - Trio (GeneDx)			
	Exome - Duo (Invitae)			

Concert Genetics Genetic Testing: Exome and Genome Sequencing for the Diagnosis of Genetic Disorders  
 V1.2024  
 Date of Last Revision: 11/2023

	Exome - Trio (Invitae)			
<a href="#">Reanalysis of Whole Exome Sequencing Data</a>	Exome Reanalysis (Ambry)	81417	F70-F79, F80-F89, Q00.0-Q99.9	4, 10, 12
<a href="#">Rapid Exome Sequencing</a>	XomeDxXpress (GeneDx)	81415, 81416	F70-F79, F80-F89, Q00.0-Q99.9	2, 6, 7, 14
	ExomeNext-Rapid (Ambry)			
	PGxome RAPID Exome Test (PreventionGenetics, part of Exact Sciences)			
	STAT Whole Exome Sequencing (PerkinElmer Genomics)			
<a href="#">Standard Genome Sequencing</a>	Genomic Unity Whole Genome Analysis - Proband (Variantyx Inc.)	0212U	F70-F79, F80-F89, Q00.0-Q99.9	7, 8, 9, 11, 13, 14
	Genomic Unity® Whole Genome Analysis - Comparator (Variantyx Inc.)	0213U		
	GenomeSeqDx (GeneDx)	81425, 81426		
	TruGenome Trio (Illumina)			
	Whole Genome Sequencing (PerkinElmer Genomics)			
	MNGenome (MNG Laboratories)			
	Praxis Whole Genome Sequencing (Praxis Genomics LLC)	0265U		
	Praxis Combined Whole Genome Sequencing and Optical Genome Mapping (Praxis Genomics LLC)	0267U		
<a href="#">Rapid Genome Sequencing</a>	Rapid Whole Genome Sequencing (Rady Children’s Institute for Genomic Medicine)	0094U	F70-F79, F80-F89, Q00.0-Q99.9	2, 14
	RCIGM Rapid Whole Genome Sequencing, Comparator Genome (Rady)	0425U		

	Children’s Institute for Genomic Medicine)			
	RCIGM Ultra-Rapid Whole Genome Sequencing (Rady Children’s Institute for Genomic Medicine)	0426U		
	Ultra-Rapid Whole Genome Sequencing (Rady Children’s Institute for Genomic Medicine)	81425, 81426		
	STAT Whole Genome Sequencing (PerkinElmer Genomics)			
	MNGenome STAT (Labcorp/MNG Laboratories)			

## OTHER RELATED POLICIES

This policy document provides criteria for exome and genome sequencing for the diagnosis of genetic disorders in patients with suspected genetic disorders and for population-based screening. Please refer to:

- ***Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies*** for criteria related to exome and genome sequencing of solid tumors and hematologic malignancies.
- ***Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay*** for criteria related to diagnostic genetic testing performed after a child has been born.
- ***Genetic Testing: Prenatal and Preconception Carrier Screening*** for criteria related to prenatal carrier screening, preimplantation genetic testing, or preconception carrier screening.
- ***Genetic Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss*** for criteria related to prenatal exome sequencing.
- ***Genetic Testing: General Approach to Genetic and Molecular Testing*** for criteria related to exome and genome sequencing that is not specifically discussed in this or another non-general policy.

## CRITERIA

It is the policy of health plans affiliated with Centene Corporation® that the specific genetic testing noted below is **medically necessary** when meeting the related criteria:

### STANDARD EXOME SEQUENCING

- I. Standard exome sequencing (81415, 81416, 0214U, 0215U), with [trio testing](#) when possible, is considered **medically necessary** when:
  - A. The member/enrollee meets one of the following:
    1. The member/enrollee has unexplained epilepsy diagnosed at any age, **OR**
    2. The member/enrollee has [developmental delay](#) or [intellectual disability](#) with onset prior to age 18 years, **OR**
    3. The member/enrollee was diagnosed with one or more congenital anomalies before the age of 1 year, **OR**
    4. The etiology of the member/enrollee's features is most likely genetic, based on **EITHER** of the following:
      - a) Multiple congenital abnormalities affecting unrelated organ systems, **OR**
      - b) **TWO** of the following:
        - (1) Abnormality of at least one organ system, **OR**
        - (2) Dysmorphic features, **OR**
        - (3) Encephalopathy, **OR**
        - (4) Symptoms of a complex neurodevelopmental disorder (e.g., dystonia, hemiplegia, spasticity/hypertonia, epilepsy, hypotonia), **OR**

- (5) Family history strongly suggestive of a genetic etiology, including consanguinity, **OR**
  - (6) Clinical or laboratory findings suggestive of an inborn error of metabolism, **AND**
  - B. The member/enrollee has not previously had whole genome sequencing, **AND**
  - C. Alternate etiologies have been considered and ruled out when possible (e.g., environmental exposure, injury, infection, isolated prematurity), **AND**
  - D. Clinical presentation does not fit a well-described syndrome for which rapid single-gene or targeted multi-gene panel testing is available, **AND**
  - E. A diagnosis cannot be made in a timely manner by standard clinical evaluation, excluding invasive procedures such as muscle biopsy, **AND**
  - F. There is a predicted impact on the health outcome, including impact on medical management based on the results, **AND**
  - G. Pre- and post-test counseling by an appropriate provider, such as a Medical Geneticist, Genetic Counselor, or an Advanced Practice Nurse in Genetics (APGN), **AND**
  - H. The member/enrollee and member/enrollee's family history have been evaluated by a Medical Geneticist, Genetic counselor or an Advanced Practice Nurse in Genetics (APGN).
- II. Repeat standard exome sequencing (81415, 81416, 0214U, 0215U) is considered **not medically necessary**.
  - III. Standard exome sequencing (81415, 81416, 0214U, 0215U) is considered **investigational** for all other indications, including screening asymptomatic/healthy individuals for genetic disorders.

[back to top](#)

## **REANALYSIS OF WHOLE EXOME SEQUENCING DATA**

- I. Reanalysis of whole exome sequencing data (81417) is considered **medically necessary** when\*:

- A. The member/enrollee previously had whole exome sequencing at least 18 months ago, **AND**
  - B. The results of prior whole exome sequencing were non-diagnostic.
- II. Reanalysis of whole exome sequencing data (81417) is considered **not medically necessary** for all other indications.

\*If reanalysis of whole exome data is not possible, see the whole genome sequencing criteria for additional coverage information.

[back to top](#)

## **RAPID EXOME SEQUENCING**

- I. Rapid exome sequencing (81415, 81416) is considered **medically necessary** when:
- A. The member/enrollee is an acutely-ill infant (12 months of age or younger), **AND**
  - B. The member/enrollee and member/enrollee's family history have been evaluated by a Medical Geneticist, Genetic Counselor, or an Advanced Practice Nurse in Genetics (APGN), **AND**
  - C. Non-genetic etiologies have been considered and ruled out when possible (e.g., environmental exposure, injury, infection, isolated prematurity), **AND**
  - D. A genetic etiology is considered a likely explanation for the phenotype, based on **EITHER** of the following:
    - 1. Multiple congenital abnormalities affecting unrelated organ systems, **OR**
    - 2. **TWO** of the following:
      - a) Abnormality affecting at least one organ system, **OR**
      - b) Dysmorphic features, **OR**
      - c) Encephalopathy, **OR**
      - d) Symptoms of a complex neurodevelopmental disorder (e.g., dystonia, hemiplegia, spasticity, epilepsy, hypotonia), **OR**

- e) Family history strongly suggestive of a genetic etiology, including consanguinity, **OR**
  - f) Clinical or laboratory findings suggestive of an inborn error of metabolism, **AND**
- E. Clinical presentation does not fit a well-described syndrome for which rapid single-gene or targeted multi-gene panel testing is available, **AND**
- F. A diagnosis cannot be made in a timely manner by clinical evaluation and other standard laboratory tests/imaging, etc., excluding invasive procedures such as muscle biopsy, **AND**
- G. There is a predicted impact on the health outcome, including impact on medical management during the hospitalization based on the results, **AND**
- H. Pre- and post-test counseling by an appropriate provider, such as a Medical Geneticist, a Genetic Counselor, or an Advanced Practice Nurse in Genetics (APGN), **AND**
- I. The member/enrollee does **not** have any of the following:
- 1. Isolated Transient Neonatal Tachypnea
  - 2. Isolated unconjugated hyperbilirubinemia
  - 3. Isolated Hypoxic Ischemic Encephalopathy with clear precipitating event
  - 4. Isolated meconium aspiration
- II. Rapid exome sequencing (81415, 81416) is considered **investigational** for all other indications.

[back to top](#)

## **STANDARD GENOME SEQUENCING**

- I. Standard genome sequencing (81425, 81426, 0212U, 0213U, 0265U, 0267U) is considered **medically necessary** when:
  - A. The member/enrollee previously had uninformative whole exome sequencing (WES), **AND**



1. WES reanalysis is not possible, **OR**
- B. The member/enrollee meets at least one of the following:
  1. The member/enrollee has unexplained epilepsy diagnosed at any age, **OR**
  2. The member/enrollee has developmental delay or intellectual disability with onset prior to age 18 years, **OR**
  3. The member/enrollee was diagnosed with one or more congenital anomalies before the age of 1 year, **OR**
  4. The etiology of the member/enrollee's features is most likely genetic, based on **EITHER** of the following:
    - a) Multiple congenital abnormalities affecting unrelated organ systems, **OR**
    - b) **TWO** of the following criteria are met:
      - (1) Abnormality of at least one organ system, **OR**
      - (2) Dysmorphic features, **OR**
      - (3) Encephalopathy, **OR**
      - (4) Symptoms of a complex neurodevelopmental disorder (e.g., dystonia, hemiplegia, spasticity/hypertonia, epilepsy, hypotonia), **OR**
      - (5) Family history strongly suggestive of a genetic etiology, including consanguinity, **OR**
      - (6) Clinical or laboratory findings suggestive of an inborn error of metabolism, **AND**
  5. Alternate etiologies have been considered and ruled out when possible (e.g., environmental exposure, injury, infection, isolated prematurity), **AND**
  6. Clinical presentation does not fit a well-described syndrome for which rapid single-gene or targeted multi-gene panel testing is available, **AND**

7. There is a predicted impact on the health outcome, including impact on medical management based on the results, **AND**
  8. Pre- and post-test counseling and evaluation by an appropriate provider, such as a Medical Geneticist, Genetic counselor or an Advanced Practice Nurse in Genetics (APGN)
- C. Standard genome sequencing (81425, 81426, 0212U, 0213U, 0265U, 0267U) is considered investigational for all other indications, including screening asymptomatic/healthy individuals for genetic disorders.

[back to top](#)

## **RAPID GENOME SEQUENCING**

- I. Rapid genome sequencing (81425, 81426, 0094U, 0425U, 0426U) is considered **medically necessary** when:
  - A. The member/enrollee is an acutely-ill infant (12 months of age or younger), **AND**
  - B. The member/enrollee and member/enrollee's family history have been evaluated by a Medical Geneticist, Genetic Counselor or an Advanced Practice Nurse in Genetics (APGN) **AND**
  - C. The etiology of the member/enrollee's features is not known and a genetic etiology is considered a likely explanation for the phenotype, based on **EITHER** of the following:
    1. Multiple congenital abnormalities affecting unrelated organ systems, **OR**
    2. **TWO** of the following:
      - a) Abnormality affecting at least one organ system, **OR**
      - b) Encephalopathy, **OR**
      - c) Symptoms of a complex neurodevelopmental disorder (e.g., dystonia, hemiplegia, spasticity, epilepsy, hypotonia), **OR**

- d) Family history strongly suggestive of a genetic etiology, including consanguinity, **OR**
  - e) Clinical or laboratory findings suggestive of an inborn error of metabolism, **OR**
  - f) Abnormal response to therapy, **AND**
- D. Alternate etiologies have been considered and ruled out when possible (e.g., environmental exposure, injury, infection, isolated prematurity), **AND**
- E. Clinical presentation does not fit a well-described syndrome for which rapid single-gene or targeted panel testing is available, **AND**
- F. rGS is more efficient and economical than the separate single-gene tests or panels that would be recommended based on the differential diagnosis (e.g., genetic conditions that demonstrate a high degree of genetic heterogeneity), **AND**
- G. A diagnosis cannot be made in a timely manner by standard clinical evaluation, excluding invasive procedures such as muscle biopsy, **AND**
- H. There is a predicted impact on health outcomes, including immediate impact on medical management during the hospitalization based on the results, **AND**
- I. Pre- and post-test counseling by an appropriate provider, such as a Medical Geneticist, Genetic Counselor, or an Advanced Practice Nurse in Genetics (APGN), **AND**
- J. The member/enrollee does **not** have any of the following:
- 1. Isolated Transient Neonatal Tachypnea
  - 2. Isolated unconjugated hyperbilirubinemia
  - 3. Isolated Hypoxic Ischemic Encephalopathy with clear precipitating event
  - 4. Isolated meconium aspiration
- II. Rapid genome sequencing (81425, 81426, 0094U, 0425U, 0426U) is considered **investigational** for all other indications.

[back to top](#)

## NOTES AND DEFINITIONS

1. **Exome Sequencing (ES)** is a genomic technique for sequencing all of the protein-coding regions of genes in the genome (also known as the exome).
2. **Genome Sequencing (GS)** is a genomic technique for sequencing the complete DNA sequence, which includes protein coding as well as non-coding DNA elements.
3. **Trio Testing** includes testing of the child and both biological/genetic parents and increases the chances of finding a definitive diagnosis, while reducing false-positive findings.
4. **Comparator Exome Sequencing** is used only for comparison with the proband (individual undergoing exome sequencing) and is used to inform the pathogenicity of variants. A comparator exome is typically one or both biological/genetic parents to the proband.
5. **Congenital anomalies** according to ACMG are multiple anomalies not specific to a well-delineated genetic syndrome. These anomalies are structural or functional abnormalities usually evident at birth, or shortly thereafter, and can be consequential to an individual's life expectancy, health status, physical or social functioning, and typically require medical intervention.
6. **Developmental delay** is a slow-to-meet or not reaching milestones in one or more of the areas of development (communication, motor, cognition, social-emotional, or adaptive skills) in the expected way for a child's age
7. **Intellectual disability (ID)** is defined by the DSM-V as:
  - a. Deficits in intellectual functions, such as reasoning, problem solving, planning, abstract thinking, judgment, academic learning, and learning from experience, confirmed by both clinical assessment and individualized, standardized intelligence testing.
  - b. Deficits in adaptive functioning that result in failure to meet developmental and sociocultural standards for personal independence and social responsibility. Without ongoing support, the adaptive deficits limit functioning in one or more activities of daily life, such as communication, social participation, and independent living, across multiple environments, such as home, school, work, and community.
  - c. Onset of intellectual and adaptive deficits during the developmental period.

[back to top](#)

## CLINICAL CONSIDERATIONS

Trio testing is preferred whenever possible. Testing of one available parent is a valid alternative if both are not immediately available and one or both parents can be done later if needed. Exome sequencing or genome sequencing can reveal incidental findings or secondary findings. These findings are defined as results that are not related to the indication for undergoing the sequencing, but may be of medical value or utility. Disclosure of these findings has been a topic of intense debate within the medical genetics community. In 2013, ACMG published recommendations for reporting secondary findings that included a list of conditions to be included. The list currently includes 59 genes that confer highly-penetrant and medically actionable conditions.

Pre-test and post-test genetic counseling that facilitates informed decision-making, the possibility to identify secondary finding with the option to ‘opt out’ of receiving these results, elicits patient preferences regarding secondary and/or incidental findings if possible, and formulates a plan for returning such results before testing occurs is strongly advised.

If a genetic diagnosis is not found by ES or GS, periodic reanalysis of the previously obtained genomic sequence is recommended. Reevaluation can occur on the variant-level or case-level. Any variants identified and reported prior to the current ACMG variant classification standards should be reevaluated using the current ACMG standards.

[back to top](#)

## BACKGROUND AND RATIONALE

### Standard Exome Sequencing

*American College of Medical Genetics and Genomics (ACMG)*

In 2021, ACMG published an evidence-based clinical practice guideline on exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability (Manickam, 2021), which included the following:

- ACMG recommends using exome or genome sequencing as a first- or second-tier test for patients diagnosed with one or more congenital anomalies before the age of 1, or for patients with intellectual disability/developmental delay before the age of 18. (p. 2031)

- ACMG recommends exome or genome sequencing for active and long-term clinical management of the proband, as well as for implications on family-focused and reproductive outcomes. (p. 2032)
- These guidelines also recommend consideration of exome sequencing after the results of chromosome microarray or focused genetic testing are uninformative for a patient with one or more congenital anomaly or patients with developmental delay/intellectual disability. (p. 2031)

Of note, ACMG states that “Isolated autism without ID or congenital malformation is formally out of scope for this recommendation but evaluation of exome/genome studies is ongoing.” (p. 2034)

ACMG also released a systematic evidence-based review (Malinowski, 2020) of 167 published studies examining the clinical impact of exome sequencing (ES) and genome sequencing (GS) in individuals with congenital anomalies (CA), developmental delay (DD), and intellectual disability (ID). This systematic review “provide[d] indirect evidence of the clinical and personal utility of ES/GS for patients with CA/DD/ID and their family members, noting that a “change in clinical management” resulted in over half of the patients examined as a result of their ES/GS results. (p. 1001)

#### *National Society for Genetic Counselors*

The National Society for Genetic Counselors (NSGC) released a position statement (2013, updated 2020) stating the following in regard to secondary and incidental findings in genetic testing:

“The National Society of Genetic Counselors strongly advises pre-test counseling that facilitates informed decision-making, elicits patient preferences regarding secondary and/or incidental findings if possible, and formulates a plan for returning such results before testing occurs.

Germline and somatic genetic testing, in both clinical and research contexts, may identify secondary findings and incidental findings as a part of the test performed. Secondary findings are purposely analyzed as part of the test, but unrelated to the primary testing indication. Incidental findings are detected unexpectedly during the analysis, and also unrelated to the primary testing indication. Both of these types of variants may be disclosed as a part of the return-of-results process.

The pre-test counseling process should establish clear expectations for what categories of results will and will not be returned. Healthcare practitioners conducting the informed consent and return-of-results processes for broad genomic testing and screening should

ensure that their patients have access to practitioners with genetic expertise, such as genetic counselors.”

The National Society of Genetic Counselors (NSGC) published evidence-based practice guidelines for individuals with unexplained epilepsy (Smith et al, 2022). The NSGC recommendations are as follows (p. 4):

- Individuals with unexplained epilepsy should be offered genetic testing, without limitation of age.
- Multi-gene, comprehensive testing, such as exome sequencing, genome sequencing or a multigene panel as a first-tier test is strongly recommended

*Patient-centered Laboratory Utilization Guidance (PLUGS)*

PLUGS developed an expert-written exome sequencing coverage policy as part of their insurance alignment focus. Their policy includes the following criteria for exome sequencing:

- The patient and family history have been evaluated by a Board -Certified or Board -Eligible Medical Geneticist, or an Advanced Practice Nurse in Genetics (APGN) credentialed by either the Genetic Nursing Credentialing Commission (GNCC) or the American Nurses Credentialing Center (ANCC), **AND**
- A genetic etiology is considered the most likely explanation for the phenotype, based on EITHER of the following:
  - Multiple congenital abnormalities affecting unrelated organ systems
  - **TWO** of the following criteria are met:
    - abnormality affecting at minimum a single organ system significant neurodevelopmental disorder (e.g., global developmental delay, intellectual disability, and/or period of unexplained developmental regression)
    - symptoms of a complex neurological condition (e.g., dystonia, hemiplegia, spasticity, epilepsy, myopathy, muscular dystrophy)
    - severe neuropsychiatric condition (e.g., schizophrenia, bipolar disorder, Tourette syndrome, self-injurious behavior, reverse sleep-wake cycles)
    - family history strongly suggestive of a genetic etiology, including consanguinity
    - laboratory findings suggestive of an inborn error of metabolism
- Alternate etiologies have been considered and ruled out when possible (e.g., environmental exposure, injury, infection), **AND**

- Clinical presentation does not fit a well -described syndrome for which single gene or targeted panel testing (e.g., comparative genomic hybridization [CGH]/chromosomal microarray analysis [CMA]) is available, **AND**
- WES is more efficient and economical than the separate single gene tests or panels that would be recommended based on the differential diagnosis (e.g., genetic conditions that demonstrate a high degree of genetic heterogeneity), **AND**
- A diagnosis cannot be made by standard clinical work -up, excluding invasive procedures such as muscle biopsy, **AND**
- Predicted impact on health outcomes, as above, **AND**
- Pre- and post-test counseling by an appropriate provider (as deemed by the Health Plan policy), such as an American Board of Medical Genetics or American Board of Genetic Counseling-certified Genetic Counselor

*Rehm et al (2023)*

Traditional genetic testing strategies have included single gene analysis or multi-gene panels as a first line test, which may still be the most appropriate test for a patient. However, there is increasing evidence that exome or genome sequencing may be more elucidating options. A 2023 paper by Rehm et al on behalf of the Medical Genome Initiative, which analyzed the rate of variants of uncertain significance (VUS) in 1,463,812 multigene panels, 42,165 exome sequencing tests, and 6,329 genome sequencing tests across 19 North American clinical laboratories, demonstrated that exome and genome sequencing had a significantly lower VUS rate (22.5%) compared to multigene panels (32.6%). (p. 5 and 6)

**Reanalysis of Whole Exome Sequencing Data***Tan, et al*

A study from 2020 examined data from 58 unsolved cases referred for any indication to evaluate the systematic reanalysis of singleton exome sequencing (ES). The authors performed a reanalysis at multiple timepoints following initial testing, and ultimately suggest that an interval of greater than 18 months from the original report may be optimal for reanalysis. (p. 1)

*Alfares, et al.*

This study from 2018 compared the detection rates of whole-exome sequencing (WES) and whole-genome sequencing (WGS) in a clinical setting. The study included 108 patients with negative array CGH and negative or inconclusive WES results. WGS was performed on all patients, and the



results of the study showed that 30% of the positive cases identified by WGS could be identified by reanalyzing WES raw data, and WGS achieved an only 7% higher detection rate. (p. 1328) The paper concluded that, although WGS is a more powerful tool than WES, in this study, “we showed that WGS has additional, but limited, clinical utility compared with reanalyzing WES data, and until the cost of WGS approximates that of WES, reanalyzing WES raw data is recommended before performing WGS.” (p. 1333)

#### *American College of Medical Genetics*

A statement from ACMG (Deignan, 2019) included considerations for case-level exome re-analysis, which include the following:

- Significant improvements have been made to bioinformatics handling of the data (alignment/variant calling and/or the automated filtering processes)
- Updated clinical and family history information, which may result in the identification of additional variants that are associated with the indication(s) for testing. (p. 1269)

### **Rapid Exome Sequencing**

#### *Kingsmore SF, Cakici JA, Clark MM et al. 2019*

This report is from the NSIGHT2 study, a prospective randomized, controlled, blinded trial (RCT) in acutely ill infants, primarily from the NICU, PICU, and CVICU at Rady Children’s Hospital, San Diego (RCHSD) to compare the effectiveness and outcomes between rWGS and rWES, with analysis as singleton probands and familial trios. The inclusion criteria for the 1,248 ill infants defined the maximum age at the time of admission as four months. They found that 24% of infants undergoing rapid exome sequencing had genetic disease. They conclude that diagnostic testing in infants with diseases of unknown etiology, rapid genomic sequencing, including rapid exome sequencing can be performed as a first tier test in infants with diseases of unknown etiology at time of admission to ICUs. In unstable infants and in those whom a genetic diagnosis was likely to impact immediate management, rapid genomic sequencing had optimal analytic and diagnostic performance by virtue of shortest time to results. (p. 725)

#### *Patient-centered Laboratory Utilization Guidance (PLUGS)*

PLUGS developed an expert-written rapid genome sequencing coverage policy as part of their insurance alignment focus. This policy references multiple primary research publications with examples of clinical presentations that result in evidence of clinical utility.

They recommend rapid whole genome testing criteria to include acutely ill infants 12 months of age or younger whose features suggest an unknown genetic etiology and have a complex phenotype which may include a combination of multiple congenital anomalies, encephalopathy, symptoms of a complex neurodevelopmental disorder, family history suggestive of genetic etiology, laboratory findings suggestive of an inborn error of metabolism and an abnormal response to therapy. The clinical presentation should not fit a well-described syndrome for which rapid single gene or targeted panel testing is available. They suggest that there should be predicted impact on health outcomes, including immediate impact on medical management based on the molecular results. (p. 3-4)

Additionally, the PLUGS Exome Sequencing policy acknowledges that exome sequencing “is typically not an appropriate first -tier test, but can be appropriate if initial testing is unrevealing, or if there is no single-gene or panel test available for the particular condition, or if a rapid diagnosis for a critically-ill child is indicated.” (p. 1)

#### *Rehm et al (2023)*

Traditional genetic testing strategies have included single gene analysis or multi-gene panels as a first line test, which may still be the most appropriate test for a patient. However, there is increasing evidence that exome or genome sequencing may be more elucidating options. A 2023 paper by Rehm et al on behalf of the Medical Genome Initiative, which analyzed the rate of variants of uncertain significance (VUS) in 1,463,812 multigene panels, 42,165 exome sequencing tests, and 6,329 genome sequencing tests across 19 North American clinical laboratories, demonstrated that exome and genome sequencing had a significantly lower VUS rate (22.5%) compared to multigene panels (32.6%). (p. 5 and 6)

### **Standard Genome Sequencing**

#### *American College of Medical Genetics and Genomics (ACMG)*

A 2021 revision, published by Rehder, et al, on next-generation sequencing for constitutional variants in the clinical laboratory states the following:

“... Exome Sequencing or Genome Sequencing provide[s] a broad approach to match detected variants with the clinical phenotype assessed by the laboratory and health-care provider. Exome Sequencing/Genome Sequencing approaches are most appropriate in the following scenarios: (1)

when the phenotype is complex and genetically heterogeneous; (2) when the phenotype has unusual features, an atypical clinical course, or unexpected age of onset; (3) when the phenotype is associated with recently described disease genes for which disease-targeted testing is unavailable; (4) when focused testing has been performed and was nondiagnostic; (5) when sequential testing could cause therapeutic delays; or (6) when the phenotype does not match an identified genetic condition, suggesting the possibility of more than one genetic diagnosis, which has been documented in 4–7% of positive cases. When Exome Sequencing/Genome Sequencing does not establish a diagnosis, the data can be reanalyzed. The potential impact of secondary findings with Exome Sequencing/Genome Sequencing should also be considered (section E.3).” (p. 1400-1401)

*Abul-Husn et al.*

In this study, performed in 2023, there were twice as many diagnoses in pediatric patients using whole genome sequencing (WGS) compared to targeted gene panel testing. The group concluded that genome sequencing may yield up to twice as many diagnoses in pediatric patients compared to targeted gene panel testing, but not yet across all population groups.

*Chung, et al*

A meta-analysis from 2023 compared the diagnostic and clinical utility of whole-exome sequencing (WES) versus whole-genome sequencing (WGS) in an ethnically diverse population of children and adults with rare disease. Results showed a similar diagnostic rate, although the odds of diagnosis by WGS was 1.2 times greater than WES. (p. 11) Meta-analysis of WES and WGS groups demonstrated that the pooled clinical utility of WGS (0.61) was higher than WES (0.48). (p. 13) The rate of variants of unknown significance (VUS) by WES and WGS did not differ significantly. (p. 15)

*Patient-centered Laboratory Utilization Guidance (PLUGS)\**

\*Of note, the following guidelines were used for whole genome sequencing (WGS) test recommendations. Although they are focused on whole exome sequencing, it is the position of Concert Genetics that the recommendations could be extrapolated to WGS, as there are currently no specific guidelines for the use of this testing.

PLUGS developed an expert-written exome sequencing coverage policy as part of their insurance alignment focus. Their policy includes the following criteria for exome sequencing:

- The patient and family history have been evaluated by a Board -Certified or Board -Eligible Medical Geneticist, or an Advanced Practice Nurse in Genetics (APGN) credentialed by either the Genetic Nursing Credentialing Commission (GNCC) or the American Nurses Credentialing Center (ANCC) **AND**
- A genetic etiology is considered the most likely explanation for the phenotype, based on EITHER of the following:
  - Multiple congenital abnormalities affecting unrelated organ systems
  - **TWO** of the following criteria are met:
    - abnormality affecting at minimum a single organ system significant neurodevelopmental disorder (e.g., global developmental delay, intellectual disability, and/or period of unexplained developmental regression)
    - symptoms of a complex neurological condition (e.g., dystonia, hemiplegia, spasticity, epilepsy, myopathy, muscular dystrophy)
    - severe neuropsychiatric condition (e.g., schizophrenia, bipolar disorder, Tourette syndrome, self-injurious behavior, reverse sleep-wake cycles )
    - family history strongly suggestive of a genetic etiology, including consanguinity
    - laboratory findings suggestive of an inborn error of metabolism
- Alternate etiologies have been considered and ruled out when possible (e.g., environmental exposure, injury, infection), **AND**
- Clinical presentation does not fit a well -described syndrome for which single - gene or targeted panel testing (e.g., comparative genomic hybridization [CGH]/chromosomal microarray analysis [CMA]) is available, **AND**
- WES is more efficient and economical than the separate single -gene tests or panels that would be recommended based on the differential diagnosis (e.g., genetic conditions that demonstrate a high degree of genetic heterogeneity), **AND**
- A diagnosis cannot be made by standard clinical work-up, excluding invasive procedures such as muscle biopsy, **AND**
- Predicted impact on health outcomes, as above, **AND**
- Pre- and post-test counseling by an appropriate provider (as deemed by the Health Plan policy), such as an American Board of Medical Genetics or American Board of Genetic Counseling-certified Genetic Counselor

*National Society of Genetic Counselors*

The National Society of Genetic Counselors (NSGC) published evidence-based practice guidelines for individuals with unexplained epilepsy (Smith et al, 2022). The NSGC recommendations are as follows (p. 4):

- Individuals with unexplained epilepsy should be offered genetic testing, without limitation of age.
- Multi-gene, comprehensive testing, such as exome sequencing, genome sequencing or a multigene panel as a first-tier test is strongly recommended.

### *Rehm et al (2023)*

Traditional genetic testing strategies have included single gene analysis or multi-gene panels as a first line test, which may still be the most appropriate test for a patient. However, there is increasing evidence that exome or genome sequencing may be more elucidating options. A 2023 paper by Rehm et al on behalf of the Medical Genome Initiative, which analyzed the rate of variants of uncertain significance (VUS) in 1,463,812 multigene panels, 42,165 exome sequencing tests, and 6,329 genome sequencing tests across 19 North American clinical laboratories, demonstrated that exome and genome sequencing had a significantly lower VUS rate (22.5%) compared to multigene panels (32.6%). (p. 5 and 6)

## **Rapid Genome Sequencing**

### *Patient-centered Laboratory Utilization Guidance (PLUGS)*

PLUGS developed an expert-written rapid genome sequencing coverage policy as part of their insurance alignment focus. This policy references multiple primary research publications with examples of clinical presentations that result in evidence of clinical utility.

They recommend rapid whole genome testing criteria to include acutely ill infants 12 months of age or younger whose features suggest an unknown genetic etiology and have a complex phenotype which may include a combination of multiple congenital anomalies, encephalopathy, symptoms of a complex neurodevelopmental disorder, family history suggestive of genetic etiology, laboratory findings suggestive of an inborn error of metabolism and an abnormal response to therapy. The clinical presentation should not fit a well-described syndrome for which rapid single gene or targeted panel testing is available. They suggest that there should be predicted impact on health outcomes, including immediate impact on medical management based on the molecular results. (p. 3-4)

*Rehm et al (2023)*

Traditional genetic testing strategies have included single gene analysis or multi-gene panels as a first line test, which may still be the most appropriate test for a patient. However, there is increasing evidence that exome or genome sequencing may be more elucidating options. A 2023 paper by Rehm et al on behalf of the Medical Genome Initiative, which analyzed the rate of variants of uncertain significance (VUS) in 1,463,812 multigene panels, 42,165 exome sequencing tests, and 6,329 genome sequencing tests across 19 North American clinical laboratories, demonstrated that exome and genome sequencing had a significantly lower VUS rate (22.5%) compared to multigene panels (32.6%). (p. 5 and 6)

[back to top](#)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed.	03/23	03/23
Semi-annual review. Updated title to reflect V1.2024 version. Throughout policy: replaced “coverage criteria” with “criteria. Overview, coding, reference-table, background and references updated. For Overview: added “GS has been shown to have...”. For Other Related Policies: added “and Molecular”. For Standard Exome Sequencing: under I.A.1. added “diagnosed”; under I.A.2. removed “etiology of the member/enrollee’s features...” and replaced with “member/enrollee has developmental delay...”; under I.A.3. added “The member/enrollee was diagnosed...”; added I.A.4. added “The etiology of the member/enrollee’s features...”; under I.A.4.b. removed “criteria are met” and added “Abnormality of at least one”; under I.B. added “The member/enrollee has not previously...”; under I.F. removed “during the hospitalization”; under I.G. replaced “Board Certified...” with “Medical Geneticist” and added “(APGN)”; under I.H. removed “Board Certified...” and added “Genetic Counselor”; under II. removed “for the above indications...” and added “is considered not medically necessary”; removed II.A. “Significant new symptoms...”; removed II.B. “The member/enrollee has been re-evaluated...”; removed II.C. “There have been improvements...”; removed III. “Repeat standard exome...” and added “Standard exome sequencing...”; added “Reanalysis of Whole Exome Sequencing Data...”. For Rapid Exome Sequencing: under I.B. removed “Board Certified...” and replaced with “Medical Geneticist...”; under I.B. added “AND”; under I.C. added “Non-genetic etiologies...”; under I.D.2. removed “criteria are met”; under I.2.a. removed “significantly” and “minimum a single” and added “least one”; under I.D.2.d. removed “Dysmorphic features, OR”;	10/23	10/23

Reviews, Revisions, and Approvals	Revision Date	Approval Date
<p>for I.D. removed “Alternate etiologies...”; under I.F. removed “standard” and added “and other standard laboratory...”; under I.H. removed “Board Certified” and added “(APGN)”. For Standard Genome Sequencing Panel: removed “0209U...” and added “0212U...”; under I.A. added “The member/enrollee previously had...” under I.A.1. added “WES reanalysis...”; under I.B. added “The member/enrollee meets...” under I.B.1. added “The member/enrollee has unexplained...”; under I.B.2. added “The member/enrollee has developmental...”; under I.B.3. added “The member/enrollee was diagnosed...”; under I.B.4. added “The etiology of the member/enrollee’s...”; under I.B.4.a. added “Multiple congenital abnormalities...”; under I.B.4.b. added “TWO of the following...”; under I.B.4.b.1. added “Abnormality...” under I.B.4.b.2. added “Dysmorphic features...”; under I.B.4.b.3. added “Encephalopathy...”; under I.B.4.b.4. added “Symptoms of a complex...”; under I.B.4.b.5. added “Family history strongly...”; under I.B.4.b.6. added “Clinical or laboratory...”; under I.B.5. added “Alternate etiologies...”; under I.B.6. added “Clinical presentation...”; under I.B.7. added “There is a predicted...”; under I.B.8. added “Pre-and post-test...”; under I.C. added “Standard genome sequencing...”. For Rapid Genome Sequencing Panel: under I.B. removed “Board -Certified...” and added “Genetic Counselor”; under I.C.2. removed “criteria are met.”; under I.C.2.a. removed “significantly” and “minimum a single” and added “least one”; under I.I. removed “Board Certified” and added “(APGN)”; under I.J. replaced “scutely ill infant” with “member/enrollee” and removed “diagnoses:”. For Clinical Considerations: removed “While trio sequencing...”; removed “When appropriate, retesting...”; removed “Variant-level reanalysis...”; removed “Case-level reanalysis...”. For Background and Rationale: added “which included the following.”; added “for patients”; added “Of note, ACMG...”; removed “In regards to repeat exome sequencing...”; removed “UpToDate...”; removed “Rapid Genome Sequencing...”; added “Traditional genetic testing...”; added “Reanalysis of Whole Exome Sequencing Data...”; added “Rapid Exome Sequencing...”; for Standard Genome Sequencing: added “A 2021 revision...”; removed “Sequencing may be performed...”; removed “(section E.6); added “Abul-Husn, et al...”; added “Chung, et al...”; added “Patient-centered Laboratory...”; added “National Society of Genetic Counselors...”; added “Rehm et al (2023)...”. For Rapid Genome Sequencing: removed “(p.3)”; added “Rehm et al (2023)...”.</p>		
<p>Added CPT codes 0425U, 0426U to the policy reference table and criteria for Rapid Genome Sequencing.</p>	<p>11/23</p>	

## REFERENCES

1. Malinowski J, Miller DT, Demmer L, et al. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. *Genet Med*. 2020;22(6):986-1004. doi:10.1038/s41436-020-0771-z
2. “Rapid Genome Sequencing”. Seattle Children’s Hospital Patient-centered Laboratory Utilization Guidance Services. [http://www.schplugins.org/wp-content/uploads/Rapid-Genome-Sequencing-Policy\\_FINAL\\_Oct-2019.pdf](http://www.schplugins.org/wp-content/uploads/Rapid-Genome-Sequencing-Policy_FINAL_Oct-2019.pdf). October 2019.
3. “Secondary and Incidental Findings in Genetic Testing”. Position Statement from National Society of Genetic Counselors. <https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements/Position-Statements/Post/secondary-and-incidentalfindings-in-genetic-testing-1>. Released September 27, 2013. Updated March 23, 2020.
4. Deignan JL, Chung WK, Kearney HM, et al. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2019;21(6):1267-1270. doi:10.1038/s41436-019-0478-1
5. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) [published online ahead of print, 2021 Jul 1]. *Genet Med*. 2021;10.1038/s41436-021-01242-6. doi:10.1038/s41436-021-01242-6
6. Kingsmore SF, Cakici JA, Clark MM, et al. A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in Ill Infants. *Am J Hum Genet*. 2019;105(4):719-733. doi:10.1016/j.ajhg.2019.08.009
7. “Exome Sequencing”. Seattle Children’s Hospital Patient-centered Laboratory Utilization Guidance Services. [Whole Exome Sequencing\\_IBC](#) (schplugins.org) October 2019.
8. Rehder C, Bean LJH, Bick D, et al. Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(8):1399-1415. doi:10.1038/s41436-021-01139-4
9. Smith L, Malinowski J, Ceulemans S, Peck K, Walton N, Sheidley BR, Lippa N. Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors. *J Genet Couns*. 2022 Oct 24. doi: 10.1002/jgc4.1646. Epub ahead of print. PMID: 36281494.



10. Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. *Genet Med.* 2018;20(11):1328-1333. doi:10.1038/gim.2018.41
11. Abul-Husn NS, Marathe PN, Kelly NR, et al. Molecular diagnostic yield of genome sequencing versus targeted gene panel testing in racially and ethnically diverse pediatric patients [published online ahead of print, 2023 May 5]. *Genet Med.* 2023;100880. doi:10.1016/j.gim.2023.100880
12. Tan NB, Stapleton R, Stark Z, et al. Evaluating systematic reanalysis of clinical genomic data in rare disease from single center experience and literature review. *Mol Genet Genomic Med.* 2020;8(11):e1508. doi:10.1002/mgg3.1508
13. Chung CCY, Hue SPY, Ng NYT, et al. Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations [published online ahead of print, 2023 May 13]. *Genet Med.* 2023;100896. doi:10.1016/j.gim.2023.100896
14. Rehm HL, Alaimo JT, Aradhya S, et al. The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change. *Genet Med.* Published online July 30, 2023;100947.

[back to top](#)

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and

limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

Concert Genetics Genetic Testing: Exome and Genome Sequencing for the Diagnosis of  
Genetic Disorders  
V1.2024  
Date of Last Revision: 11/2023

©2023 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.